Nitisinone Dipharma

Nitisinone, the active ingredient in Nitisinone Dipharma, is a p‑Hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor presented as an oral tablet for oral use. It is used to treat hereditary tyrosinemia type I and is being investigated for alkaptonuria in affected patients. GNH USA supplies Nitisinone Dipharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Nitisinone acts on the tyrosine degradation pathway and is indicated for the following conditions: - Hereditary tyrosinemia type I: reduces accumulation of toxic metabolites and improves liver function. - Alkaptonuria (investigational): aims to lower homogentisic acid production and mitigate disease progression.

Nitisinone may cause a range of adverse reactions. Patients should be monitored for both frequent and less common events.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: may occur after dosing. - Vomiting: occasional, often self‑limiting. - Abdominal pain: mild discomfort reported. - Fatigue: general tiredness. - Elevated liver enzymes: mild transaminase rise.

Serious or Rare Side Effects: - Hepatic failure: signs of severe liver injury. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hypersensitivity: rash, pruritus, or anaphylaxis. - Elevated serum tyrosine: may lead to ocular complications. - Neurological disturbances: rare encephalopathy. - Metabolic acidosis: uncommon but serious.

Before initiating therapy, clinicians should consider several safety measures. - Liver function monitoring: assess baseline and periodic transaminases. - Serum tyrosine levels: regular measurement to avoid excessive accumulation. - Dietary protein restriction: limit high‑tyrosine foods as advised. - Concomitant medications: review for potential interactions affecting metabolism. - Pregnancy and lactation: use only if benefits outweigh risks, as data are limited. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Nitisinone can interact with other medicines; awareness of the interaction level helps guide management.

Major Interactions (Avoid): - Other HPPD inhibitors: combined use may increase toxicity. - Highly protein‑bound drugs: competition may alter plasma concentrations. - Drugs causing hepatic injury: additive risk to liver function.

Moderate Interactions (Monitor Closely): - Antihypertensives: monitor blood pressure for changes. - Oral contraceptives: efficacy may be reduced, consider alternative methods. - Vitamin A supplements: monitor for signs of excess. - Warfarin: observe INR values for potential variation.